Public Sector Pension Investment Board lifted its holdings in RadNet, Inc. (NASDAQ:RDNT – Free Report) by 82.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 444,754 shares of the medical research company’s stock after buying an additional 201,643 shares during the period. Public Sector Pension Investment Board’s holdings in RadNet were worth $31,847,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently added to or reduced their stakes in RDNT. Bank of America Corp DE grew its holdings in RadNet by 15.1% during the first quarter. Bank of America Corp DE now owns 589,610 shares of the medical research company’s stock valued at $32,953,000 after purchasing an additional 77,198 shares during the period. Edmond DE Rothschild Holding S.A. bought a new position in shares of RadNet during the 2nd quarter valued at approximately $1,172,000. Legal & General Group Plc bought a new stake in RadNet during the 2nd quarter worth approximately $9,787,000. California State Teachers Retirement System boosted its position in shares of RadNet by 25.4% in the first quarter. California State Teachers Retirement System now owns 77,646 shares of the medical research company’s stock worth $4,340,000 after purchasing an additional 15,746 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of RadNet during the 2nd quarter valued at $1,163,000. 77.90% of the stock is currently owned by institutional investors.
RadNet Stock Down 3.2%
NASDAQ RDNT opened at $69.51 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.90. RadNet, Inc. has a 52 week low of $50.82 and a 52 week high of $85.84. The firm has a market capitalization of $5.48 billion, a price-to-earnings ratio of 133.00 and a beta of 1.42. The company has a fifty day moving average of $72.83 and a two-hundred day moving average of $65.56.
RadNet (NASDAQ:RDNT – Get Free Report) last released its earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.08. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. The firm had revenue of $638.26 million during the quarter, compared to analyst estimates of $639.97 million. During the same quarter last year, the business earned $0.20 EPS. The business’s revenue was up 22.1% on a year-over-year basis. On average, analysts predict that RadNet, Inc. will post 0.56 earnings per share for the current year.
Insider Activity at RadNet
In other news, EVP Mital Patel sold 44,661 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $78.51, for a total value of $3,506,335.11. Following the sale, the executive vice president directly owned 155,514 shares in the company, valued at approximately $12,209,404.14. This represents a 22.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.14% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on RDNT. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Barclays raised their target price on shares of RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Raymond James Financial reiterated a “strong-buy” rating on shares of RadNet in a research note on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a research note on Wednesday, November 4th. Finally, KeyCorp boosted their price target on shares of RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.67.
Get Our Latest Report on RadNet
RadNet Company Profile
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Featured Articles
- Five stocks we like better than RadNet
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT – Free Report).
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
